GB2379166A - Animal feed - Google Patents

Animal feed Download PDF

Info

Publication number
GB2379166A
GB2379166A GB0224534A GB0224534A GB2379166A GB 2379166 A GB2379166 A GB 2379166A GB 0224534 A GB0224534 A GB 0224534A GB 0224534 A GB0224534 A GB 0224534A GB 2379166 A GB2379166 A GB 2379166A
Authority
GB
United Kingdom
Prior art keywords
feed
compound
peptidoglycan
composition according
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0224534A
Other versions
GB0224534D0 (en
Inventor
Arie Karst Kies
Alexander Ferdinand Arendsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke DSM NV
Original Assignee
DSM NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM NV filed Critical DSM NV
Priority to GB0224534A priority Critical patent/GB2379166A/en
Publication of GB0224534D0 publication Critical patent/GB0224534D0/en
Publication of GB2379166A publication Critical patent/GB2379166A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813Exopeptidases (3.4.11. to 3.4.19)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/158Fatty acids; Fats; Products containing oils or fats
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/189Enzymes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/10Feeding-stuffs specially adapted for particular animals for ruminants
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/80Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

Animal feeds comprising a compound that disrupts the peptidoglycan layer of bacteria and a compound that disrupts the phospholipid layer of bacteria are disclosed. The feed is particuarly active against Gram negative bacteria which possess both a lipopolysaccharide/lipid outer layer, and an inner peptidoglycan layer. The compounds can act synergistically against bacteria, and therefore improve the growth or the feed conversion ratio of animals. The feed may be fed to monogastric and/or non-ruminant animals such as poultry, pigs, piglets, (veal) calves or fish. The phospholipid disrupting compound can be a phospholipase, polyunsaturated fatty acid (PUFA, such as arachidonic acid) or a chelating agent (such as EDTA). The peptidoglycan disrupting layer can be an enzyme, such as an endoglycosidase or a peptidase, that can either hydrolyse peptidoglycan or cleave peptide crosslinks. The enzyme is preferably lysozyme.

Description

<Desc/Clms Page number 1>
ANIMAL FEED Field of the Invention The present application relates to animal feeds, or additives or premixes therefor, that contain a compound that can disrupt the peptidoglycan layer of bacteria (e. g. lysozyme), and a compound that can disrupt the (inner and/or outer) phospholipid layer of bacteria (e. g. arachidonic acid, phospholipase). These two compounds can synergistically act as antimicrobial agents.
Background of the Invention Farm, monogastric and/or non-ruminant animals such as pigs, piglets, poultry, calves, veal calves and fish are grown intensively for the production of meat, fish and eggs.
These animals are fed diets containing a variety of raw materials of animal and/or vegetable origin to supply energy and protein. Most of the feed that is consumed is produced commercially by the compound feed industry, but a significant part is produced on the farm and fed directly. The feed is often supplemented with vitamins and minerals to meet the animal's nutrient requirements. The use of industrially produced enzymes in these feeds has now almost become common practice. Enzymes include phytases, amylases, proteases, glucanases, endoxylanases and mannanases. However, feed costs are the most important cost factor in animal production.
These enzymes are used to promote growth and feed conversion, and to reduce the environmental pollution produced by manure from pigs, poultry and fish. While antibiotics have been routinely added to animal feed, it has been reported that human pathogenic bacteria could develop a resistance against those or related antibiotics has been increasing rapidly. This has made it more difficult to cure people from bacterial infections, and the widespread use of antibiotics in animal feed has been blamed by various experts in the acceleration of build-up resistance to various antibiotics. This has led to a ban on the use of most antibiotics as growth promoters in animal feed in the European Union. It is likely
<Desc/Clms Page number 2>
that other countries will follow these examples due to pressure from consumer and healthcare organisations. The feed industry is therefore more interested in natural additives with growth promoting effects, without any therapeutic side effects in humans.
WO-A-00/21381 (DSM N. V. ) refers to animal feeds, which contain at least two antimicrobial enzymes and a polyunsaturated fatty acid (PUFA). One of these enzymes can be lysozyme. At that time it was not realised that a PUFA could disrupt the outer phospholipid layer of bacteria, and while it was known that the PUFA was beneficial, its mechanism was unknown, and therefore its use as a compound for disrupting the outer phospholipid layer was not disclosed in that document. Indeed this document does not contain a general disclosure of using a phospholipid-disrupting agent in animal feed.
Other documents that refer to antimicrobial effects for more than one component include: (a) a combination of a chimeric peptides (a hybrid of cecropin and melittin) and lysozyme (Winans et al., Biochemistry 38: 11710 (1999)), (b) a combination of lysozyme, hydrogen peroxide and ascorbic acid (T. E.
Miller, J. Bacterial 98: 949 (1969) ), where the H202 oxidises the ascorbic acid; (c) lysozyme and EDTA, hydrogen peroxide or ascorbic acid (Am. J. Physiol.
Cell Physio. 279: 799 (2000) ) ; and (d) human secreted phospholipase A2 and lysozyme or lysostaphin (Buckland et al., Biochimica et Biophysica Acta 1484:/95-26 (2000) ), although animal feed is not disclosed and the combinations were not tested against live bacteria.
Description of the Invention The present invention provides an animal feed, or an additive or premix composition therefor, comprising two components that show antimicrobial synergy. This may allow the improvement of growth and feed conversion ratio of farm, monogastric and/or non ruminant animals such as pigs, piglets, poultry, calves, veal calves and aquatic animals such as fish. This can allow one to reduce the amount of, or omit, an antibiotic (as a growth promoter).
The first aspect of the present invention relates to an animal feed composition, comprising :
<Desc/Clms Page number 3>
(a) a compound that disrupts the peptidoglycan layer of bacteria; and (b) a compound that disrupts the (inner and/or outer) phospholipid layer of bacteria.
Composition of the Bacterial Cell Wall Based on colour formation following staining, bacteria can be divided into two classes, namely Gram positive and Gram negative bacteria. These two classes differ both in the composition and the structure of their cell walls. The major component for both Gram positive and Gram negative bacteria cell walls is peptidoglycan. The peptidoglycan is a thick rigid layer consisting of an overlapping lattice of two sugars that are cross-linked by amino acid bridges. The exact molecular structure of this layer is species specific.
The two sugars are N-acetyl glucosamine and N-acetylmuramic acid, which are linked through a B-l, 4-glycoside bond. Attached to N-acetylmuramic acid, which is a compound uniquely found in bacterial cell walls, is a side chain usually consisting of four amino acids. The most commonly found amino acids are L-alanine, D-alanine, D-glutamic acid, and a di-basic amino acid, usually diaminopimelic acid. The N-acetylglucosamine, Nacetylmuramic acid and the amino acid side chain forms a single peptidoglycan unit that can link with other units via covalent bonds to form a repeating polymer.
The polymer is further strengthened by crosslinks between the third amino acid (Dglutamic acid) of one unit and the fourth amino acid (diaminopimelic acid) of the next glycan tetrapeptide. The linker peptide of some bacteria contain glycine, serine and threonine. The degree of crosslinking determines the degree of rigidity. Peptidoglycan can be thought of as a strong woven mesh that holds the cell shape. It is not an impermeable barrier, since the openings in the mesh are large enough for many molecules to pass through them.
The cell walls of Gram positive bacteria consist almost entirely of the peptidoglycan layer, which forms a heavy cross-linked woven structure that wraps around the cell. It is very thick with peptidoglycan accounting for about 50% of the weight of the cell, and 90% of the weight of the cell wall. It is about 20 to 80nm thick.
The cell walls of Gram negative bacteria contain markedly less peptidoglycan, only 15 to 20% of the cell wall being made up of peptidoglycan, and this is only partially crosslinked.
<Desc/Clms Page number 4>
Gram negative bacteria further differ from their Gram positive counterparts in that their cell wall contains an extra lipid layer. This is an outer membrane which primarily contains lipopolysaccharides (LPS), phospholipids, proteins and a small amount of peptidoglycan. It encloses the periplasmic space. The lipopolysaccharide consists of a core region to which are attached repeating units of polysaccharide. Components of this outer membrane are associated with endotoxic activity. In particular, the lipid portion of this membrane contains lipid A, a toxic compound that is responsible for most of the pathogenic effects associated with harmful Gram negative bacteria.
Compounds that Disrupt the Peptidoglycan Layer This includes compounds that can lyse or degrade the cell wall. They may be able to cleave peptidoglycan. The compound may be a protein, such as an enzyme.
The compound may be an endoglycosidase, for example it may cleave or degrade peptidoglycan or glycopeptide. It may cleave B-l, 4-glycosidic bonds. In particular, it may cleave between the C ofN-acetylmuramic acid and C4 of N-acetylglucosamine.
Particularly preferred is lysozyme.
Other suitable enzymes are endoactylmuramidases (also fulfilled by lysozyme) and endoacetylglucosamidases, and exoacetylglucosamidases.
Preferably the compound is an enzyme, which is able to hydrolyse peptidoglycan from the bacterial cell wall. This may include glycosidases (for example which hydrolyse a polysaccharide chain), glucosamidases (for example endo-N-acetylglucosamidases), endoor exo-peptidases (which can split peptide crosslinks) and peptidases or carbohydrases.
Enzymes that can therefore disrupt the crosslinking tetrapeptides, such as proteases, peptidases and amidases are included. These include acetyl muramyl-L-alanine amidases, intrapeptide hydrolases, lysostaphin (glycyl-glycine endopeptidase), L-alanine and glycine amino peptidase, L-alanine and glycine carboxypeptidase. Of these, N-acetylmuramyl-Lalanine amidase (NAMLAA, EC 3.5. 1.28) is particularly preferred (this cleaves between polysaccharides and polypeptides). The human or mammalian form of this enzyme may be employed. Mucanolysin may also be used.
Carbohydrases include endoacetylmuramidases (which split the linkage N-acetylmuramyl-N-acetylglucosamine), endoacetylglucosaminidases (which split
<Desc/Clms Page number 5>
N-acetylglucosaminyl-N-acetylmuramic acid) and exo-acetylglucosamidases. Acetyl- muramyl-L-alanine amidases can split the N-acetylmuramyl-L-alanine linkage. Peptidases include both endo-peptidases and exo-peptidases. These can split a variety of linkages, including alanyl-glycine, alanyl-alanine, alanyl-lysine, glycyl-glycine and alanyl-meso- DAP. The amount of the compound is preferably such that it is effective, e. g. antimicrobial, or that it can disrupt the peptidoglycan layer (of bacteria).
Preferably the enzyme is (e. g. freely) soluble in water. It may be thermostable.
Lysozyme is the preferred compound for disrupting the peptidoglycan layer. This may be provided in the animal feed at from 1,000 to 1,000, 000 or 10,000, 000, such as from 5,000 or 10,000 to 150,000 or 1,000, 000, more preferably from 15,000 or 25,000 to 100,000 or 500,000 Shugar units per kilogram of animal feed. Preferably, this first enzyme may be present at an amount, by weight, to give a final concentration in the animal feed of from 0.04 to 44 milligrams per kg of feed, preferably from 0.2 or 0.4 to 6.7 or 20 milligrams per kg of feed, and more preferably from 0.8 or 1.1 to 4.4 or 10 (e. g. 1 to 5) milligrams per kg of feed, e. g. in the case of HEWL (Hen Egg White Lysozyme).
The lysozyme may be from a natural source, such as (e. g. hen) egg white. It may also be recombinant. For example, it may be expressed in an Aspergillus species, such as Aspergillus niger.
Other suitable compounds for disrupting the peptidoglycan layer include glycocalyx-disrupting compounds. This may be a bismuth salt.
Compounds that Disrupt the Phospholipid Layer Such a compound may disrupt the inner and/or (preferably) the outer phospholipid layer. It may be a protein, such as an enzyme, or an organic or inorganic compound. The compound may be a surfactant or detergent, a chelating agent or an insect glycopeptide.
The amount of the compound may be an effective amount, e. g. antimicrobial, or that it can disrupt the phospholipid layer (of bacteria).
Suitable compounds include polyunsaturated fatty acids (PUFAs). A PUFA may be present in the animal feed at no more than 100 g, such as no more than 10 g, preferably no
more than 1 g per kg of animal feed. Even lower concentrations of PUPA may be used, for example at least O. OOOlg, such as at least O. OOlg, preferably at least 0. 002g per kg of feed.
Suitable amounts are from 0. 1 to 0. 0001 g of PUFA per kg of feed, preferably from 0. 02 or
<Desc/Clms Page number 6>
0.05 to 0.002 g of PUFA per kg of feed and more preferably from 0.01 to 0.004 g of PUFA per kg of feed.
These amounts refer to the weight of the PUFA, and so if the PUFA is added in the form of an oil (e. g. having for example from 30 to 40% of the PUFA), then the amount of oil present (or added) can be calculated accordingly, for example by multiplying the amount of the PUFA by 100/X where X is the percentage of the PUFA in the oil. Hence, for example with a 30 or 35 to 40,45 or 50% PUFA content, the amount of oil that can be added may vary proportionally, such as from 0.33 or 0.25 down to 0.00033 or 0.00025g of oil per kg of feed. Other amounts and intermediate ranges can be calculated on the same basis, starting with the figures for the PUFA in the previous paragraph.
The PUFA may be an 0-3 or an 0-6 PUFA. Preferably it is present in an oil, e. g. an edible oil. The oil may be microbial or single cell oil or a vegetable oil. Preferably the PUFA is in a liquid form, such as will occur if it is present in an oil. Preferred PUFAs are C,,, C20 or C22 (#-6 or Q-3) PUFAs.
Preferred 03 and #6 PUFAs include: (Q3) docosahexaenoic acid (DHA, 22: 6 03), suitably from algae or fungi, such as the (dinoflagellate) Crypthecodinium or the fungus Traustochytrium ; (06) y-linolenic acid (GLA, 18: 3 Q6) ; (03) a-linolenic acid (ALA, 18: 3 fob) ; conjugated linoleic acid (CLA, octadecadienoic acid); (Q6) dihomo-y-linolenic acid (DGLA, 20: 3 06) ; (06) arachidonic acid (ARA, 20: 4 06) ; and (. 03) eicosapentaenoic acid (EPA, 20: 5 03).
Preferred PUFAs include ARA, DHA, EPA and/or GLA. ARA is particularly preferred. The PUFA may be from a natural (e. g. vegetable or marine source) or may be derived from a single cell, algal or microbial source.
A microbial oil may thus comprise an 03 or an Q6 PUFA. The H3 PUFA (e. g.
DHA)-containing oil may be a marine, e. g. fish (such as tuna) oil. The Q6 and/or #3 PUFA (e. g. ARA, DHA or EPA)-containing oil can be a microbial or single cell oil.
An Q6 and/or D3 PUFA-containing microbial oil (e. g. GLA, ARA and EPA) can be obtained from fungi, such as Mortierella, Pythium or Entomophthora. Q3 PUFAs (e. g.
EPA) can be produced from algae such as Porphyridium or Nitzschia. Preferably, the
<Desc/Clms Page number 7>
microbial (or Q6 or 03 (e. g. ARA, DHA or EPA containing) ) oil can be produced by a single cell or a microorganism. This may be a bacteria, yeast, algae or fungi. Preferred fungi are of the order Mucorales. The fungus may be of the genus Mortierella, Phycomyces,
Blakeslea, Aspergillus, Thraustochytrium, Pythium or Entomophthora. Preferred fungi are of the species Mortierella alpina, Blakeslea trispora, Pythium insidiosum and Aspergillus terreus.
Preferred yeasts are of the genus Pichia or Saccharomyces, for example Pichia ciferrii. Bacteria can be of the genus Propionibacterium. Preferred algae are dinoflagellate and/or belong to the genus Crypthecodinium, for example are of the species
Crypthecodinium cohnii.
The Q6 and/or Q3 PUFA-containing oil may be a vegetable oil. These include blackcurrant, borage and primrose oils, and often contain an Q6 PUFA, e. g. GLA. They also include olive, sunflower and soybean, soy (flower) oils, for example cooking and/or salad oils.
The PUFA may be in the free fatty acid form, or an ester form, such as a triglyceride. If it is present in an oil, then preferably at least 50%, such as at least 60%, or at least 70%, of the PUFA is in triglyceride form. However, the amount of triglyceride may be higher, such as at least 85%, 90% or at least 95% of the oil. Of these triglycerides, preferably at least 40%, 50% and suitably at least 60% of the PUFA is present at the aposition of the glycerol (present in the triglyceride backbone), also known as the 1 or 3 position.
The PUFA can be in the form of a free fatty acid, salt, fatty acid ester (e. g. a methyl or ethyl ester), as a phosopholipid and/or in the form of a triglyceride.
The PUFA may be present in or derived from a plant (or part of a plant, for example if the plant is transgenic or has been modified genetically).
The PUFA may act by being a surfactant. Other non-PUFA surfactants are contemplated, including tri-n-butylphosphate, cetylpyridinium chloride and/or glycerol mono-oleate.
In some embodiments it is preferred that the or each compound (e. g. PUFA) is still present inside the microorganism (that produced it). Hence the compound may be added as microorganism cells, such as biomass. The cells may be mixed with the animal feed (or with one or more feed substance (s) or ingredients). The microorganism may produce one
<Desc/Clms Page number 8>
or more of the two types of compounds.
In a typical PUFA production (by fermentation) process the amount of PUFA produced may be from 7 to lOg/kg broth (i. e. wet biomass). Hence the amount of broth (we cells) to be added, or present in, the feed composition can be calculated by multiplying the amount of PUFA desired by a factor of 70 or 100 (e. g. lOg broth/kg feed gives a PUPA concentration of 0. 1 glkg feed). If a dried biomass is added or used instead, then the dired cells can have a PUFA amount of 100 to 200, such as 140 to 180g/kg cells, and so to obtain the amount of PUFA one multiplies the amount of PUFA by 10 or 20 to give the amount of dried cells per kg feed.
The phospholipid-disrupting layer compound may be a peptide, such as a glycopeptide or a thiopeptide. The compound may thus be a cecropin, defencin, attacin, melittin, proline rich peptide, diptericin, pleurocidin, trichogin, alexomycin or nisin.
The compound may be a chelating agent, for example one bearing a negative charge. It may therefore chelate a positive ion, for example of valency II. This may include alkaline earth metals, such as calcium and magnesium. A suitable chelating agents include EDTA (ethylene diamine tetra acetic acid), CDTA, HDTA, NTA and/or IDA.
Other compounds include bile salts (such as deoxycholate, organic or inorganic acids (lactic acid, hydrochloric acid, ascorbic acid), other enzymes (rhodanese), imidazols (such as miconazol), or cinnamon aldehyde.
A further example of a phospholipid disrupting compound is the enzyme phospholipase A2 (PLA2). This may be from a mammalian, such as a human, source. The use of this enzyme in animal feeds is already known (EP-A-0,743, 017). Other phospholipases may be used, and these include phospholipase A, (EC 3.1. 1.32), phospholipase B (lysophospholipase), phospholipase C and phospholipase D.
Phospholipase A2 has the activity EC 3.1. 1.4.
The phospholipase may be from a natural source, or it may be produced recombinantly, for example by expression of a heterologous gene in a microorganism, for example in Kluveromyces lactis or Aspergillus. The phospholipase may be present as an inactive pro-form that can be activated on ingestion, for example in the GI tract, suitably by proteolytic processing.
The phospholipase may be added to a feed at a concentration which varies according to the type of phospholipase employed, and the target animal. However, as a guideline, the
<Desc/Clms Page number 9>
concentration of a phospholipase is from 1,000 to 5 million IU (International Units) per kg of phospholipid, such as from 10, 000 to 500,000. The definition of the International Unit for phospholipase activity can be found in Example 1 ofEP-A-0, 743,017.
This enzyme may be present at a concentration to give from 5 to 5,000, preferably from 10 to 2,500, and more preferably from 50 to 1,000 Egg Yolk Units (EYU) per kilogram of animal feed. One EYU is defined as the amount of phospholipase enzyme that releases 1 umol of acid per minute from egg lecithin at pH 8 and 40 C.
Thus, preferably the enzyme (or compound) may be present at an amount, by weight, to give a final concentration in the animal feed of from 0.005 to 5 (or 10 or 20) milligrams per kg of feed, preferably from 0. 01 or 0. 025 to 2.5 or 4 milligrams per kg of feed, and more preferably from 0.05 or 0.1 to 1.0 or 0.7 milligrams per kg of feed, for example in the case of pig pancreas PLA2 produced in A. niger.
In the animal feed, the concentration of phospholipid may be from 0.5 g to 10.0 g
per kg of feed. Consequently, the phospholipase may be present in a range of from 0. 5 to 50, 000 IU per kg feed, preferably from 5, 0 to 5, 000 IU per kg of feed. Of course, the dosage of phospholipase can be adjusted, if the phospholipid content of the feed is outside this range, or is not present at all.
Preferably the phospholipase is PLA2. This has been expressed in various organisms, such as E. coli, Saccharomyes cerevisiae and Aspergillus niger. It is therefore expected successful (e. g. heterologous) expression of this phospholipase can be obtained in a wide range of microorganisms. PLA2 hydrolyses phospholipids in the cell wall, such as phospholidylglycerol. Enzymes that have this activity (ofPLA) can thus be used in the invention.
If the animal feed comprises a phospholipid, it is preferably a lecithin. IfPLA2 is used, then preferably then this is from a mammalian source, such as from a bovine, porcine, murine rat or human source.
Bacteria As mentioned before, the animal feeds of the present invention are active against bacteria, in particular Gram negative bacteria, as these have both the lipid/lipopolysaccharide layer as well as the peptidoglycan layer. A non-exhaustive list of
<Desc/Clms Page number 10>
Gram negative bacteria which the compositions in the present invention can be useful against is provided below.
Family (-) Genera Species Acetobacteriaceae Acetobacter, Gluconobacter, Frateuria A. aceti Alcaligenaceae Alcaligenes, Deleya, Achromobacter A. faecalis Bacteroidaceae Bacteroides, Porphyromonas, Fusobacterium, Leptotrichia and Selenomonas S. rumantium Chromatiaceae Ameobobacter, Chromatium, Lamprobacter C. okenii Lamprocystis, Thiocapsa, Thyocystis Thiodictyon, Thiopedia, Thiospirillum Enterobacteriaceae Escherichia, Salmonella, Shigella, Erwinia, E. coli Enterobacter, Serratia Legionellaceae Legionella L. pneumophila Neisseriaceae Neisseria, Kingella, Eikenella, Simonsiella N. gonorrheae Alysiella Nitrobacteriaceae Nitrobacter, Nitrospena, Nitrococus, Nitrospira N. winogradskyi Pseudomonadaceae Pseudomonas, Xanthomonas, Zoogloea, Fraturia P. aruginosa Rhizobiaceae Rhizobium, Bradyrhizobium, Azorhizobium, R. laguminosarum Sinorhizobium Rickettsiaceae Rickettsia, Rochalimae, Ehrlichia, Cowdria Neorickettsia Spirochaetaceae Triponema, Borrelia T. pallidum Vibrionaceae Vibrio, Aeromonas, Plesiomonas and V. cholera Photobacterium
Of these Gram negative bacteria, suitable are those of the genera Vibrio, Neisseria, or Salmonella.
Although effective against Gram negative bacteria, the compounds used in the invention can also be active against Gram positive bacteria. Suitable Gram positive bacteria are listed below.
<Desc/Clms Page number 11>
Family (+) Genera Species (Lacto) Bacillaceae (Lacto) bacillus, Sporolactobacillus B. botulinum Sporocarcina, Filibacter, Cayophanum B. cereus, Clostridium, Desulphatomaculum B. coagulas B. mycroides B. pumilis B. subtilis B. thuringiensis Micrococcaceae Arthrobacter, aa4-Micrococcus M luteus, M. roseus, M. lysoeiktus, M. radiochrans Mycobacteriaceae Mycobacterium (including genus Corynebacteria, Propionibacteria and Bifidobacteria) Nocardia, Rhodococcus M. tuberculosis Peptococcaceae Peptococcus, Peptostreptococcus P. niger Ruminococcuss, Sarcina, Coprococcus
The Gram positive bacteria are suitably of the group Cornynebacteria, Propionibacteria, Clostridia, Lactobacilli and/or Bifidobacteria.
Animal Feed Compositions The compounds, if enzymes, can be produced on industrial scale and/or may be recombinant. Lysozyme is commercially available, isolated from egg white, or may be recombinant. The enzyme may be naturally occurring or may be a (e. g. recombinant) variant or mutant thereof.
The compound is preferably recombinantly produced such as by expression of a heterologous gene or cDNA in a suitable organism, or alternatively by homologous (over) expression of a suitable endogenous gene. The glucose oxidase gene, for example, has been overexpressed in recombinant systems (WO-A-89/12675, Chiron). Lysozyme (from egg white) can be recombinantly expressed by expression of the gene in Aspergillus
<Desc/Clms Page number 12>
niger (Archer, D. B. et al., Bio/Technology 8: 741-745 (1990) ). A lysozyme mutant (produced by protein engineering) can also be used which may have better heat stability and/or stronger antimicrobial action.
A second aspect of the invention relates to a premix or additive composition to be added to one or more edible feed substance (s) or ingredient (s), for example to prepare or for supplementation feed composition (of the first aspect). This can comprise the two layerdisrupting compounds. Preferably the additive or premix comprises from 10 to 1000, such as from 25 or 50 to 750, preferably from 75 or 100 to 250 or 500, times as much of either of the two compounds as the feed. This is because the premix can be"diluted"by a factor of 10 to 1,000 (so that the premix constitutes 10% to 0. 1% of final feed) when making the animal feed. This premix may be in the form of granules or pellets.
A third aspect of the invention relates to a process for the preparation of an animal feed composition, the process comprising adding to (or supplementing) an animal feed, or to one or more edible feed substance (s) or ingredient (s), the two layer-disrupting compounds.
The (or each) compound which disrupts peptidoglycan layer and/or phospholipid layer can be added to the animal feed composition separately from any feed substance (s) or ingredient (s), individually or in combination of other feed additives. Alternatively or in addition the or each compound can be in integral part of one of the food substances. The invention includes both preparing a feed composition with the two compounds or supplementing an existing feed composition with these two compounds.
A preferred method for the addition of the or each compound to the animal feed is to add the compound as transgenic plant material and/or (e. g. transgenic) seed. This is particularly suitable if the compound is protein, such as an enzyme. The compound may have been synthesised through heterologous gene expression, for example the gene encoding the desired enzyme may be cloned into a plant expression vector, under control of the appropriate plant expression signals, for example a tissue specific promoter, such as a seed specific promoter. The expression vector containing the gene including the enzyme can be subsequently transformed into plant cells. Transformed cells can be selected for regeneration into plants. The thus obtained transgenic plant can be grown and harvested.
Those parts of the plants containing the heterologous (plant) protein can be included in one of the compositions of the invention, either as such or after further processing.
<Desc/Clms Page number 13>
Reference here is made to WO-A-91/14772, which discloses general methods for the (heterologous) expression of enzymes in (transgenic) plants. This includes methods for seed-specific expression of enzymes. The compound, such as the protein, may be contained in the seed of the transgenic plant. It may also however be contained in other plant parts such as roots, stems, leaves, wood, flowers, bark and/or fruit.
The addition of the compound in the form of a transgenic plant material, such as transgenic seed, may require the processing of the plant materials such as to make the compound available, or at least improve the compound's availability. Such processing techniques may include various mechanical techniques, such as milling and/or grinding, or thermomechanical treatments, such as extrusion or expansion. This may be conducted before any extraction of the compound, if necessary.
Exclusions Preferably the animal feed of the invention does not contain any antibiotics. It may be free of a (supplementary or added) mineral component (such as zinc and/or iodine) and/or an immunomodulating agent (such as ascorbic acid). The composition may not include a combination of lysozyme, glucose oxidase and arachidonic acid or lysozyme, glucose, glucose oxidase and ascorbic acid. Other excluded compositions may include
those comprising a combination ofPLA2 and lysostaphin, ascorbic acid and lysozyme, or EDTA and lysozyme.
Production of compounds by microorganisms Although one or more of the compounds can be produced by a microorganism, for many situations (the producing) micro-organisms will not be added to or present in the feed, or at least live (or viable) organisms, such as bacteria, are not present in the feed.
Hence in this case the composition is free from any microorganisms that produced one or more of these compounds (or micro-organisms from Streptomyces). Furthermore, the composition may be devoid of micro-organisms that produce lactic acid inside the animal (e. g. those of the genus Lactobacillus or Enterococcus). Typically, before addition of the compounds, the feed composition will be heated to kill, or reduce the number of, any bacteria present in the feed.
<Desc/Clms Page number 14>
Uses of animal feed A fourth aspect of the invention relates to a process for promoting growth, feed conversion or antibacterial activity, in a monogastric or non-ruminant animal, the process feeding the animal a compound that disrupts the peptidoglycan layer bacteria and a compound that disrupts the phosopholipid layer of bacteria. The animal can be fed the animal feed of the first aspect or feed preparable by the third aspect.
Suitable animals include farm, monogastric and/or non-ruminant animals such as pigs (or piglets), poultry (such as chickens, turkeys and laying hens), calves, veal calves or aquatic (e. g. marine) animals, for example fish.
A further aspect relates to the use of a composition of the second aspect as an additive for a monogastric or non-ruminant animal feed composition.
The compositions of the invention may be active in vivo (e. g. not in vitro), or only once ingested or inside the animal. The compounds may thus not be effective since the compositions may be too dry, e. g. they have a water content of no more than 10,20 or 30 or 50%. Once ingested and inside the animal (e. g. in the stomach or rumen) there may be sufficient liquid (or water) for the compounds to become active or effective (e. g. antimicrobial, or layer disrupting).
Animal Feed Components The compositions of the invention, in particular additive or premix compositions, can be either in liquid or solid form. If a solid, then this may be a powder, a granulate, extrudate or it may be pellets. For a solid form, the amount of water present may be below 20,15 or even 10%, such as from 2 to 10%, 3 to 8% or 4 to 7%. The or each compound (e. g. enzyme) may be present at from 1 to 30%, such as 2 to 20%, for example 3 to 15%, and optimally at from 4 to 14% (on a dry matter basis). The remainder may comprise carbohydrates and/or carbohydrate polymers (such as starch and/or modified starch), for example at least 70,80, 90 or 95%, such as from 75 to 90%. The composition may have a coating, for example if it is in a pellet, granulate, or extrudate form. There may thus be one or more coats on the outside of the composition, comprising one or more coating materials.
If present, the coating (or coating materials) may be present at from 1 to 10%, such as from 2 to 6%, optimally at from 3 to 5%. The composition may have one or more stabilisers (such as glycerol and/or sorbitol) and/or one or more preservatives (such as sorbate and/or
<Desc/Clms Page number 15>
benzoate).
If the composition is a liquid, then the water (or moisture) content will be higher.
The water content may be up to 40,50 or 60%, for example from 25 to 65%, optimally from 35 to 55%. If a stabiliser is present, this may be at an amount of from 45 to 65%, such as from 50 to 60%, optimally from 52 to 58%. The stabiliser is preferably sorbitol and/or glycerol.
A description of the preparation of pellets and granules, in particular carbohydrate based enzyme granulates, is described in WO-A-98/54980 (International Application No.
PCT/EP98/03327), the contents of which is incorporated by reference.
The composition may comprise a carrier which may comprise at least 15% of an edible carbohydrate polymer. The carrier may be in particulate or powder form. However, if the composition is a liquid, it may be in the form of a solution or a slurry. The polymer preferably comprises glucose, or glucose-containing units, although it can contain glucopyranose units, amylose and/or amylopeptin. In addition, or instead of starch, a glucan, peptin or glycogen can be used. Preferably at least 15%, such as at least 30%, at least 40%, for example at least 60%, optimally at least 80% of the composition (or the solid carrier) comprises the carbohydrate polymer.
Additional details of enzyme-containing compositions for animal feed can be found in WO-A-98/55599 (International Application No. PCT/EP98/03328), the contents of which is also incorporated by reference. Although this document primarily deals with phytases, its teachings are equally applicable to other compounds, in particular enzymes.
Animal feed compositions of the first aspect will usually contain one or more feed ingredients or substances. These are ingredients and substances intended for consumption by an animal, and is therefore in a form suitable for ingestion and nutrition for an animal.
This will therefore usually exclude human foodstuffs, or food substances or ingredients intended or destined for consumption by humans. Preferably the feed composition is both edible and digestible by the animal.
Suitably the substances and/or ingredients have a dry matter content of at least 80, 85,90 or 95%. The protein content of the composition (or the substances and/or ingredients) may vary considerably, but may be from 5 to 20%, such as 10 to 15%, for example vegetable and/or plant products or parts thereof, such as buckwheat, rice, wheat, barley or com. Substances or ingredients with higher protein contents, such as from 45 to
<Desc/Clms Page number 16>
95%, e. g. 50 to 80%, may be provided, for example peanuts, poultry feathers, soy bean (or products thereof), sunflower (e. g. seeds) or casein. Preferred animal feed compositions may therefore comprise one or more of oats, pea (seeds), peanuts, soy beans, sunflower, canola, casein, coconut, corn, meat, millet, potato, rice, safflower and/or wheat. Preferably the composition (and substances or ingredients) have a crude fibre content below 30%, 25%, 20%, 15% or even below 10%. Similarly, the calcium content may be below 2%, such as 1 %, below 0.5% and preferably less than 0.2%. The total phosphorous content of the
(animal feed composition) is preferably from 2 to 0. 01%, such as from 1 to 0. 1%, optimally less than 0.5%.
The precise substances and ingredients can vary depending on the animal to be fed.
An alternative composition may comprise one or more of bakery waste, sugar beet, brewers grain, canola, cassava, corn, fababean, fish (such as anchovy or herring meal), lentils, meat and/or millet.
Preferred features and characteristics of one aspect of the present invention are applicable to another aspect mutatis mutandis.
The present invention will now be described by way of example with reference to the following Examples, which are provided by way of illustration, and are not intended to limit its scope.
EXAMPLES Characterization of antimicrobial compounds Lysozyme obtained from chicken egg-white was obtained as a commercial product under the trade mark DELVOZYME TM from DSM Food Specialties, PO Box 1, 2600 MA DELFT, The Netherlands. The product contains 20 x 106 Shugar units/g product. One Shugar unit is defined as the amount of enzyme which causes a decrease of absorbance of 0.001 per minute at 450 nm and pH 6.2 at 25 C in a suspension of Micrococcus lysodeikticus (0.25 mg/ml) obtainable from Sigma Chemicals.
Phospholipase A2 was obtained through production of pig pancrease PLA2 in Aspergillus niger from DSM Food Specialties, Agri Ingredients, P. O. Box 1,2600 MA Delft, The Netherlands. This process is described in WO-A-96/36244. Phospholipase concentrations are defined by Egg Yolk Units (EYU). One EYU is defined as the amount of phospholipase enzyme that releases 1 lmol of acid per minute from egg lecithin at pH 8
<Desc/Clms Page number 17>
and 40 C.
Arachidonic acid (ARA) was obtained from DSM Food Specialties. Agri Ingredients, P. O. Box 1,2600 MA Delft, The Netherlands under the trade mark VEVODARTM. This is a microbial oil (ARA content at least 35%) obtained by culturing the fungus Mortierella spina.
Comparative Examples 1 to 3 and Example 4 Application of antimicrobial compounds in animal feed for poultry Trials we carried out with broilers to test the efficacy of arachidonic acid (ARA) and lysozyme alone and the combination of both. Male and female broilers (Ross) were used in this trial; the animals were sexed and housed separated (4 pens per sex per treatment). Upon arrival, animals we weighed, and divided into floorpens equalising the average weights and its deviation between treatments. Fifteen animals were kept per pen.
The pens were situated in an artificially heated, ventilated and illuminated broiler house.
The floor space of each pen was 0.75 m2 ; wood shavings were used as bedding material.
The broiler house was illuminated for 23 hours per day. During the experimental period, light intensity was gradually reduced. The temperature was gradually reduced from 33 C the first day to 21 C at day 28. The animals had been vaccinated against New Castle disease and Infectious Bronchitis. The experiment lasted 28 days.
The experimental diets were offered ad lib. to the animals. Water was freely available. The feed was pelleted (with temperatures below 65 C) at a diameter of 2. 5 millimeter.
The experiment comprised the following four treatments: 1) basal diet (negative control) 2) basal diet + lysozyme (50,000 Shugar units/kg of feed) 3) basal diet + arachidonic acid (ARA) to a final concentration of 0.001 g/kg of feed.
4) basal diet + lysozyme (50,000 Shugar units/kg of feed) + arachidonic acid (ARA) to a final concentration of 0.001 g/kg of feed.
Gain and feed conversion were measured. The composition of the feed (basal diets) used was: Ingredients Content (%)
<Desc/Clms Page number 18>
Rye 10 Wheat 41.85 Soy oil 2 blended animal fat 6 Rape seed meal 7.5 Soya bean meal (45.4% crude protein) 18.5 Full fat toasted soya beans 5 Soya isolate 2.5 Corn gluten meal 2.5 Vitamins/premix 1 Limestone 1.4 Monocalciumphosphate 1.2 Salt (NaCl) 0.25 L-lysine. HCL 0.14 DL-methionine 0.16 ME broilers (MJ/kg) 12.02 Crude protein (%) 22.4 Crude fat (%) 10.3 Lysine (digestible, %) 1.06 Methionine + cystine (digestible, %) 0.78 The lysozyme and arachidonic acid were added to this basal diet by mixing them first with a carrier.
The effects of the lysozyme and arachidonic acid on growth and feed conversion ratio in broilers after 28 days are shown below in Table 1.
<Desc/Clms Page number 19>
Table 1
Example Diet Feed Growth Feed Intake (g) conversion (g) ratio 1 Basal diet 2173 1319 1.65 2 Basal diet + 2169 1322 1. 64 lysozyme 3 Basal diet + 2261 1413 1. 60 arachidonic acid 4 Basal diet + lysozyme 2249 1409 1. 59 + arachidonic acid
A synergistic effect was found for the combination of ARA and lysozyme on the feed conversion ratio.
Comparative Examples 5 to 7 and Example 8 Application of antimicrobial compounds in animal feed for piglets Crossbred piglets (equal number of barrows and gilts; in total 80 animals) of a similar age and weight were used in this trial. They were housed in environmentally controlled rooms, and had ad lib. access to feed and water at all times. Temperature, ventilation and illumination were applied according to common practice. The piglets were allotted to one of four treatments. There were two piglets in each pen with 10 replications (weight blocks) per treatment. The sexes were divided evenly over the treatments. The trial started 2 weeks after weaning of the piglets, at an age of approximately 38 days, and lasted for 6 weeks.
Body weight and pen feed consumption were measured after three and after six weeks of the experiment.
The basal diet was a typical com-soybean meal diet, with the following composition: Raw Material Content (%) Corn 63.4 Soybean meal 33.73 Dicalcium phosphate 1.29 Limestone 0.74
<Desc/Clms Page number 20>
Salt (NaCl) 0.33 L-lysine. HCI 0.01 Vitamin-trace mineral premix 0.5 The diet was calculated to contain 3265 kcal ME/kg, 20.5% crude protein, 1.15% lysine and 0.68% methionine + cystine. No antibiotic was added to the feed.
The experiment comprised the following treatments (Examples 5 to 8): 5) basal diet (negative control); 6) basal diet + lysozyme (100,000 Shugar units/kg of feed) ; 7) basal diet + arachidonic acid to a final concentration of 0.001 g/kg of feed.
8) basal diet + lysozyme (100,000 Shugar units/kg of feed) + arachidonic acid to a final concentration of 0.001 g/kg of feed.
The results obtained in terms of feed intake, growth and feed conversion ratio are shown below in Table 2.
Table 2 Average effects of lysozyme and ARA on growth and feed conversion ratio in piglets (38 to 80 days of age).
Example Diet Daily Feed Daily Feed Intake (g) gain Conversion (g) Ratio 5 Basal diet 621 371 1.69 6 Basal diet + 622 375 1. 66 lysozyme 7 Basal diet + 662 395 1. 67 arachidonic acid 8 Basal diet + 649 403 1. 61 lysozyme + arachidonic acid
The combination of two different types of antimicrobial compounds (i. e. arachidonic acid and lysozyme) resulted in a surprising synergistic effect on feed conversion ratio.
<Desc/Clms Page number 21>
Comparative Examples 9 to 11 and Example 12 The use of the antimicrobial compounds lysozyme and arachidonic acid in fish nutrition.
Effects of supplemental antimicrobial compounds on growth and feed conversion ratio were studied with trout (Oncorhynchus mykiss).
The diet composition used was as follows: Raw material Content (%) Soybean meal 41 Soya beans, pressure cooked 20 Wheat gluten 22 Fish oil 13 L-Iysine-HCI 0.8 DL-methionine 0.2 Vitamin/mineral premix 3.5 No growth promoting antibiotic was added to the feed.
Experiments were conducted with 200 trout with a mean initial body weight of 9.1 g/trout which were allotted to 4 equal groups. Diets were fed to these 4 groups over a period of 49 days. The water temperature was kept constant at 15 C. The diets were fed twice daily to satiation avoiding feed losses. Weight gain and feed conversion ratio were determined.
The experiment comprised the following treatments (Examples 9 to 12): 9) basal diet (negative control); 10) basal diet + lysozyme (50,000 Shugar units/kg of feed); 11) basal diet + arachidonic acid to a final concentration of 0.001 g/kg of feed.
12) basal diet + lysozyme (50,000 Shugar units/kg of feed) + arachidonic acid to a final concentration of 0.001 g/kg of feed.
The results obtained, in terms of growth and feed conversion, are shown below in Table 3.
Table 3 Gain, feed intake and feed conversion ratio in trout fed for 49 days on diets supplemented with lysozyme +/-arachidonic acid.
<Desc/Clms Page number 22>
Example Diet Feed Gain Feed Intake (g/trout) Conversion (g/trout) Ratio 9 Basal diet 16. 4 11. 2 1. 46 10 Basal diet + 16. 3 11. 3 1. 44 lysozyme 11 Basal diet + 18. 1 12. 6 1. 44 arachidonic acid 12 Basal diet + 17. 8 12. 8 1. 39 lysozyme + arachidonic acid
The results obtained demonstrate the favourable effects of a peptidoglycan disrupting compound and phospholipid disrupting compound on growth and feed conversion ratio in trout.
Comparative Examples 13 to 15 and Example 16 The use of antimicrobial compounds Lysozyme and Phospholipase in fish nutrition Effects of supplemental antibacterial enzymes on growth and feed conversion ratio were studied with trout (Oncorhynchus mykiss). Set-up, diet composition, housing, etc. were similar to those described in Examples 9 to 12.
Experiments were conducted with 200 trout with a mean initial body weight of 9.1 g/trout which were allotted to 4 equal groups. Diets were fed to these 4 groups over a period of 49 days.
The experiment comprised the following treatments (Examples 13 to 16): 13) basal diet (negative control) 14) basal diet + lysozyme (50,000 Shugar U/kg of feed) 15) basal diet + phospholipase A ;, (PLA ; 500 EYU/kg of feed) 16) basal diet + lysozyme (50,000 Shugar Ulkg of feed) + phospholipase A2 (500 EYU/kg of feed).
The results obtained, in terms of growth and feed conversion, are shown below in Table 4.
<Desc/Clms Page number 23>
Table 4 Gain, feed intake and feed conversion ratio in trout fed for 49 days on diets supplemented with lysozyme and/or phospholipase A2.
Example Diet Feed Gain Feed Intake (g/trout) Conversion (g/trout) Ratio 13 Basal diet 16.4 11.2 1.46 14 Basal diet + 16.3 11.3 1.44 lysozyme 15 Basal diet + 16. 0 11. 3 1. 42 phospholipase 16 Basal diet + 17.1 12.3 1.39 lysozyme + phospholipase
The results obtained demonstrate again the synergistic results of a peptidoglycan disrupting compound and phospholipid disrupting compound on growth and feed conversion ratio in trout.
Example 17: in vitro tests In vitro tests were carried out to substantiate the synergistic antimicrobial effect of a combination of a peptidoglycan layer disrupting compound and a (inner and/or outer) phospholipid layer disrupting compound.
In disk diffusion (also called Bauer-Kirby) susceptibility tests, small paper disks (6 mm), impregnated with known amounts of lysozyme and/or arachidonic acid, were placed on the surface of YNB media plates that were inoculated confluently with a standardized suspension of E. coli K-12. The arachidonic acid and lysozyme, which diffuse into the media, caused a zone of inhibition of growth of E. coli around the disk.
The protocol was as follows. A sterile cotton swab was placed in E. coli K-12 suspension and excess fluid was removed by pressing and rotating the cotton against the inside of the tube above the fluid level. The swab was then streaked in at least three directions over the surface of the YNB media to obtain uniform growth. A final sweep was made around the rim of the plate. The plates were allowed to dry for five minutes. Using sterile forceps, disks containing arachidonic acid and/or lysozyme were applied onto the
<Desc/Clms Page number 24>
plates. The plates were incubated within 15 minutes after application of the disks.
Following overnight incubation, the diameter of the zone of inhibition of growth was used as a measure of susceptibility.
The paper disks were impregnated in the following solutions: A: De-ionized water B: Arachidonic acid (1 microgram/ml in deionized water) C: Lysozyme (50 Shugar units/ml in deionized water) D: Arachidonic acid (1 microgram/ml) + lysozyme (50 Shugar units/ml) in deionized water The following results were obtained:
Experiment zone of inhibited growth Experiment (mm) ~A O B 5 C 8 D 23 Comparative Examples 18 and 20 and Examples 19 and to 21 The efficacy of a combination of a mixture of lysozyme and arachidonic acid and phospholipase A.
The experimental procedures and basal feed composition was the same as for Examples 1 to 4.
The experiment comprised the following treatments : (18) basal diet (negative control) (19) basal diet + lysozyme (50,000 Shugar units/kg of feed) + arachidonic acid (ARA) to a final concentration of 0.001 g/kg of feed.
(20)'Basal diet + phospholipase A ;, (500 EYU/kg of feed) (21) basal diet + lysozyme (50,000 Shugar units/kg of feed) + arachidonic acid (ARA) to a final concentration of 0.001 g/kg of feed + phospholipase A2 (500 EYU/kg of feed).
The effects of the combination of lysozyme and arachidonic acid and phospholipase A2 on growth and feed conversion ratio in broilers after 28 days are presented in Table 5.
Table 5
<Desc/Clms Page number 25>
Example Diet Feed Growth (g) Feed conversion Intake (g) Ratio 18 Basal diet 2173 1319 1. 65 19 Basal diet + lysozyme 2249 1409 1. 59 + arachidonic acid 20 Basal diet + 2159 1347 1. 60 phospholipase 21 Basal diet + lysozyme 2241 1424 1. 57 + arachidonic acid + phospholipase
In this trial it was shown that both the combination of lysozyme and arachidonic acid (and phospholipase) significantly improved the performance of the broilers.

Claims (23)

1. An animal feed composition comprising: (a) a compound that disrupts the peptidoglycan layer of bacteria; and (b) a compound that disrupts the phospholipid layer of bacteria.
2. An animal feed additive or premix composition comprising: (a) a compound that disrupts the peptidoglycan layer of bacteria; and (b) a compound that disrupts the phospholipid layer of bacteria.
3. A composition according to claim 1 or 2 wherein the compound that disrupts the peptidoglycan layer cleaves peptidoglycan or lyses or degrades the peptidoglycan layer.
4. A composition according to any one of the preceding claims wherein the peptidoglycan disrupting compound is a protein, such as an enzyme.
5. A composition according to any preceding claim wherein the peptidoglycan disrupting compound is an endoglycosidase, endoacetylmuramidase, glucosaminidase, an endo-or exo-peptidase, or a carbohydrase.
6. A composition according to any preceding claim wherein the peptidoglycan disrupting compound is an enzyme that is soluble in water and/or thermostable.
7. A composition according to any preceding claim wherein the peptidoglycan disrupting compound hydrolyzes peptidoglycan from the cell wall, for example it cleaves peptidoglycans between muramic acid and acetylglucosamine.
8. A composition according to any preceding claim wherein the peptidoglycan disrupting compound comprises lysozyme, mutanolysin or N-acetylmuramyl-L-alanine amidase.
9. A composition according to any preceding claim wherein the peptidoglycan disrupting compound comprises lysozyme and is at a concentration of 1,000 to 10,000, 000, such as from 10,000 to 150,000, more preferably from 25,000 to 100,000 Shugar units per kilogram of animal feed.
10. A composition according to any preceding claim wherein the peptidoglycan disrupting compound comprises lysozyme at a concentration of from 0.04 to 44 milligrams per kg of feed, preferably from 0.4 to 6.7 milligrams per kg of feed, and more preferably from 1.1 to 4.4 milligrams per kg of feed.
<Desc/Clms Page number 27>
11. A composition according to any preceding claim wherein the phospholipid layer disrupting compound comprises a protein, such as an enzyme, or an organic or inorganic compound.
12. A composition according to claim 11 wherein the compound comprises a phospholipase, a polyunsaturated fatty acid (PUFA), or a chelating agent.
13. A composition according to claim 12 wherein the phospholipase is from a mammalian, e. g. human source and/or is PLA2 and is present at a concentration of from 5 to 5,000, preferably from 10 to 2,500, and more preferably from 50 to 1,000 Egg Yolk Units per kilogram of animal feed.
14. A composition according to claim 12 wherein the phospholipase is at a concentration from 0.005 to 5 milligrams per kg of feed, preferably from 0. 01 to 2.5 milligrams per kg of feed, and more preferably from 0.05 to 1.0 milligrams per kg of feed.
15. A composition according to any of claims 11 to 14 wherein the phospholipid layer disrupting compound is derived from an animal, an animal product, plant, plant product, an algae, algal product, single cell, single cell product or microorganism.
16. A composition according to claim 15 wherein the compound is of microbial origin and/or is recombinant protein.
17. A composition according to claim 12 wherein the PUFA comprises an Q-3 or Q-6 Cils, C20 or C PUFA.
18. A composition according to claim 12 wherein the PUFA is in the form of free fatty acid, salt, fatty acid ester, phospholipid or mono-, di-or triglyceride.
19. A composition according to claim 12 wherein the PUFA comprises arachidonic acid (ARA).
20. A process for the preparation of a feed composition, suitable for a monogastric or non-ruminant animal, the process comprising adding a compound that disrupts the peptidoglycan layer and a compound that disrupts the phospholipid layer of bacteria to an animal feed, or mixing a feed additive ir orenux composition according to any of claims 2 to 18 with one or more edible feed substance (s) or ingredient (s).
21. An animal feed composition comprising an additive or premix composition according to claim 2 and one or more edible feed substance (s) or ingredient (s).
22. A process for promoting growth and/or feed conversion in a monogastric or non-ruminant animal, the process comprising feeding the animal a compound that disrupts
<Desc/Clms Page number 28>
the peptidoglycan layer and a compound that disrupts the phospholipid layer bacteria or a composition as defined in any of claims 1 or 20.
23. A process according to claim 21 where the animal is monogastric and/or non ruminant such as pig, piglet, poultry, (veal) calf or aquatic animal.
GB0224534A 2002-10-22 2002-10-22 Animal feed Withdrawn GB2379166A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0224534A GB2379166A (en) 2002-10-22 2002-10-22 Animal feed

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0224534A GB2379166A (en) 2002-10-22 2002-10-22 Animal feed

Publications (2)

Publication Number Publication Date
GB0224534D0 GB0224534D0 (en) 2002-11-27
GB2379166A true GB2379166A (en) 2003-03-05

Family

ID=9946342

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0224534A Withdrawn GB2379166A (en) 2002-10-22 2002-10-22 Animal feed

Country Status (1)

Country Link
GB (1) GB2379166A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093561A1 (en) * 2003-04-22 2004-11-04 University Of Guelph Prevention and treatment of pathogenic infection in poultry and eggs
EP1677621A1 (en) * 2003-10-29 2006-07-12 Cerestar Holding B.V. Fish feed and process for preparing the same
EP1902724A2 (en) 2002-09-18 2008-03-26 Neova Technologies Inc. Antimicrobial compositions
JP2015506667A (en) * 2011-11-25 2015-03-05 ノボザイムス アクティーゼルスカブ Polypeptide having lysozyme activity and polynucleotide encoding the same
WO2017001703A1 (en) 2015-07-02 2017-01-05 Novozymes A/S Methods of improving animal performance
WO2018127532A1 (en) 2017-01-04 2018-07-12 Novozymes A/S Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
WO2019170682A1 (en) 2018-03-05 2019-09-12 Novozymes A/S Ruminant feed composition comprising a muramidase
WO2020053271A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053273A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053276A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053275A2 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053274A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020058223A1 (en) 2018-09-17 2020-03-26 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2022194728A1 (en) 2021-03-16 2022-09-22 Dsm Ip Assets B.V. Animal feed composition and use thereof
US11746363B2 (en) 2013-12-20 2023-09-05 MARA Renewables Corporation Methods of recovering oil from microorganisms
US11959120B2 (en) 2016-06-10 2024-04-16 MARA Renewables Corporation Method of making lipids with improved cold flow properties

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110754578A (en) * 2018-07-27 2020-02-07 成都大帝汉克生物科技有限公司 Compound bag capable of improving digestibility and having food calling function and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810508A (en) * 1986-10-28 1989-03-07 Spa Societa' Prodotti Antibiotici S.P.A. Process for obtaining foods free of Listeria bacteria
EP0366869A2 (en) * 1988-10-17 1990-05-09 Lycon Ag Bacteriostatic, bactericidal and antifungal composition and methods of use thereof
WO2000021381A1 (en) * 1998-10-15 2000-04-20 Dsm N.V. Antimicrobial enzymes in animal feed

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810508A (en) * 1986-10-28 1989-03-07 Spa Societa' Prodotti Antibiotici S.P.A. Process for obtaining foods free of Listeria bacteria
EP0366869A2 (en) * 1988-10-17 1990-05-09 Lycon Ag Bacteriostatic, bactericidal and antifungal composition and methods of use thereof
WO2000021381A1 (en) * 1998-10-15 2000-04-20 Dsm N.V. Antimicrobial enzymes in animal feed

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1902724A2 (en) 2002-09-18 2008-03-26 Neova Technologies Inc. Antimicrobial compositions
EP1902724A3 (en) * 2002-09-18 2008-07-02 Neova Technologies Inc Antimicrobial Compositions
WO2004093561A1 (en) * 2003-04-22 2004-11-04 University Of Guelph Prevention and treatment of pathogenic infection in poultry and eggs
EP1677621A1 (en) * 2003-10-29 2006-07-12 Cerestar Holding B.V. Fish feed and process for preparing the same
US10829750B2 (en) 2011-11-25 2020-11-10 Novozymes A/S Polypeptides having lysozyme activity and polynucleotides encoding same
US10829751B2 (en) 2011-11-25 2020-11-10 Novozyems A/S Polypeptides having lysozyme activity and polynucleotides encoding same
US9663775B2 (en) 2011-11-25 2017-05-30 Novozymes A/S Polypeptides having lysozyme activity and polynucleotides encoding same
US9701952B2 (en) 2011-11-25 2017-07-11 Novozymes A/S Polypeptides having lysozyme activity and polynucleotides encoding same
JP2015506667A (en) * 2011-11-25 2015-03-05 ノボザイムス アクティーゼルスカブ Polypeptide having lysozyme activity and polynucleotide encoding the same
US10039300B2 (en) 2011-11-25 2018-08-07 Novozymes A/S Polypeptides having lysozyme activity and compositions comprising it
US10119130B2 (en) 2011-11-25 2018-11-06 Novozymes A/S Polypeptides having lysozyme activity and compositions comprising it
US11746363B2 (en) 2013-12-20 2023-09-05 MARA Renewables Corporation Methods of recovering oil from microorganisms
EP4032409A1 (en) 2015-07-02 2022-07-27 Novozymes A/S Animal feed comprising a feed additive for improving animal performance
AU2016288515B2 (en) * 2015-07-02 2020-09-10 Dsm Ip Assets B.V. Methods of improving animal performance
US10568344B2 (en) 2015-07-02 2020-02-25 Novozymes A/S Methods of improving animal performance
WO2017001703A1 (en) 2015-07-02 2017-01-05 Novozymes A/S Methods of improving animal performance
US11959120B2 (en) 2016-06-10 2024-04-16 MARA Renewables Corporation Method of making lipids with improved cold flow properties
US11179447B2 (en) 2017-01-04 2021-11-23 Novozymes A/S Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
WO2018127532A1 (en) 2017-01-04 2018-07-12 Novozymes A/S Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
EP4052722A1 (en) 2017-01-04 2022-09-07 Novozymes A/S Compositions for human treatment
WO2019170682A1 (en) 2018-03-05 2019-09-12 Novozymes A/S Ruminant feed composition comprising a muramidase
WO2020053271A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053275A2 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053274A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053276A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053273A1 (en) 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020058223A1 (en) 2018-09-17 2020-03-26 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2022194728A1 (en) 2021-03-16 2022-09-22 Dsm Ip Assets B.V. Animal feed composition and use thereof

Also Published As

Publication number Publication date
GB0224534D0 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
AU753232B2 (en) Antimicrobial enzymes in animal feed
US20040180126A1 (en) Animal feed with low pufa concentration
Zheng et al. Exogenous enzymes as functional additives in finfish aquaculture
GB2379166A (en) Animal feed
CN107809912B (en) Animal feed composition and use thereof
Cowieson et al. Super-dosing effects of phytase in poultry and other monogastrics
Konkol et al. Biotransformation of rapeseed meal leading to production of polymers, biosurfactants, and fodder
GB2379165A (en) Animal feed
Liang et al. Application of enzymes as a feed additive in aquaculture
JP2015530876A (en) Composition for feed addition
Bimrew Effect of common feed enzymes on nutrient utilization of monogastric animals
TW201234977A (en) Feed additive composition
EP3361882A1 (en) Feed additives for aquatic animals comprising essential oils and lysozyme
CZ11197A3 (en) Use of phospholipases in feeding stuffs of animals
Caipang et al. Potential application of microbial phytase in aquaculture.
CN112689461A (en) Animal feed composition and use thereof
JPWO2004014145A1 (en) Animal feed material and animal feed made from the same
MXPA01003780A (en) Antimicrobial enzymes in animal feed
EP4297583A1 (en) Method of improving carbohydrate digestibility by a carbohydratase in an animal feed by employing serine protease
WO2022179757A1 (en) Method of improving carbohydrate digestibility by a carbohydratase in an animal feed by employing serine protease
EP4307915A1 (en) Animal feed composition and use thereof
Steinberg et al. Enzymes—‘Digestive Assistance from Aliens’
US20240156921A1 (en) Animal feed composition and use thereof
Sharma et al. A review on enzymology, uses and biotechnology of phytase
CN116887689A (en) Method for improving the digestibility of carbohydrases in animal feed by using serine proteases

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)